Management of Antithrombotic Therapy in Post PCI Patient Undergoing Pericardiotomy due to Large Pericardial Effusion : A case report
DOI:
https://doi.org/10.21776/ub.hsj.2021.002.04.9Keywords:
Antithrombotic therapy, Prcutaneous Coronary Intervention, Pericardiostomy, Pericardial Effusion.Abstract
Background : Stent thrombosis is a serious complication following percutaneous coronary intervention (PCI), and dual antiplatelet therapy (DAPT) is necessary to avoid it. Surgery, on the other hand, is a common cause for stopping DAPT. Because patients were exposed to the possibility of a major adverse cardiovascular event (MACE) when DAPT was stopped, this circumstance poses a clinical dilemma.
Objective : This case report aimed to describe the management of antithrombotic therapy in post PCI patient requiring DAPT who underwent pericardiostomy.
Case : A 69-year-old woman with large pericardial effusion without cardiac tamponade, breast cancer on chemo- therapy, heart failure stage C NYHA functional class II, chronic coronary syndrome post-DES implantation at proximal-mid LAD, and hypertension. The patient underwent pericardiotomy procedures five days after DAPT discontinuation. For the bridging therapy, continuous UFH administration was initiated at a dose of 18 IU/kg/hour after the cessation of DAPT. The UFH dose was adjusted to achieve activated partial thromboplastin time (APTT) 1.5 to 2.0 times the control value. The UFH was discontinued 6 hours before surgery. After surgery, UFH infusion was restarted 6 hours after the confirmation of hemostasis. The administration of UFH then continued until three days after DAPT was restarted. No complications were found during and after the pericar- diostomy.
Conclusion : We reported an antithrombotic treatment strategy in a post PCI patient undergoing pericardiostomy with discontinuation of DAPT, which was successfully treated with UFH without any complication. The UFH has been widely used in perioperative settings as a bridging therapy during the interruption of DAPT and may be considered in this condition.
Â
References
Banerjee S, Angiolillo DJ, Boden W, et al. Use of antiplatelet therapy/DAPT for post PCI Patients Undergoing Noncardiac Surgery. JACC. 2017;1861-70.
Van Diepen S, Tricoci P, Podder M, et al. Efï¬cacy and safety of vorapaxar in non-ST-segment elevation acute coronary syndrome patients undergoing noncardiac surgery. J Am Heart Assoc 2015;4:e002546.
Rossini R, Musumeci G, Visconti LO, et al. Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. EuroIntervention 2014;10:38–46.
Rossini R, Tarantini G, Musumeci G, et al. A Multidisiplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery. Surgery After Stenting 2. JACC. Cardiovasc Interv 2018;417–34.
Watson RD, Chin BS, Lip GY. Antithrombotic therapy in acute coronary syndromes. Clinical review. BMJ. 2002;325:1348-51.
Claessen BE, Henriques JP, Jaffer FA, et al. Stent thrombosis : A clinical perspective. JACC : Cardiovascular interventions 2014;1081-92.
Hawn MT, Graham LA, Richman JS, et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA 2013;310:1462–72.
Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000;35:1288–94.
Abualsaud AO, Eisenberg MJ. Perioperative Management of Patients With Drug-Eluting Stents. JACC : Cardiovascular interventions 2010;131-42.
Tanaka A, Ishii H, Tatami Y, et al. Unfractionated Heparin during the Interruption of Antiplatelet Therapy for Non-cardiac Surgery after Drug-eluting Stent Implantation. Intern Med 2016;55: 333-337.
Blann D, Landray MJ, Lip GY. An overview of antithrombotic therapy. Clinical review. BMJ. 2002;325:762-65.
Neumann FJ, Uva MS, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal 2018; 00:1–96.
Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal. 2017; 0, 1–48
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082–115.
Egholm G, Kristensen SD, Thim T, et al. Risk associated with surgery within 12 months after coronary drug-eluting stent implantation. J Am Coll Cardiol 2016;68:2622–32.
Mahmoud KD, Sanon S, Habermann EB, et al. Perioperative cardiovascular risk of prior coronary stent implantation among patients undergoing noncardiac surgery. J Am Coll Cardiol 2016;67: 1038–49.
Angiolillo DJ, Firstenberg MS, Price MJ, et al., BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307:265–74.
Morici N, Moja L, Rosato V, Sacco A, Mafrici A, Klugmann S, et al. Bridge with intravenous antiplatelet therapy during temporary withdrawal of oral agents for surgical procedures: a systematic review. Intern Emerg Med 2014; 9: 225-35
Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H. Coronary artery stenting and non-cardiac surgery: a prospective outcome study. Br J Anaesth 96: 686-693, 2006.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).